Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Cash Situation - from MD&A

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Aug 31, 2021 12:35pm

232 Views

Post# 33788159

RE:Cash Situation - from MD&A

I do agree and hope for the same. In the next 3 months, if we see the next 6 pending patients get 4 out 6 or better CR at 90 days, than we can confirm the trend and expect to blow way past the competition in terms of efficacy with a much less time time consuming and safer treatment. 2 vs 26-36 treatments. IMO

Eoganacht wrote:

"As of June 30, 2021, the Company has cash and cash equivalents of $5,898,912 and as a result the Company believes that it will be able to continue as a going concern for at least 12 months from the date of these unaudited condensed interim consolidated financial statements."

Hopefully by that time we will have seen a significant appreciation of the stock price.